PROVETOP

Biotinylated Human NKG2A/CD159a Protein

Catalog No: NKG2A-HB002

Species
Human
Expression System
HEK293
Tag
His, Avi
Activity
Activity verified

Product overview

Recombinant Biotinylated Human NKG2A/CD159a Protein is expressed in HEK293 cells with a His tag and Avi tag at N-terminus. It contains amino acid residues Arg100-Leu233 (UniProt accession: P26715-1).

Product Details

Molecular Aliases
NKG2A; NKG2-A; CD94; KLRD1; KP43; KLRC1; CD159A
Protein Length
Arg100-Leu233
Expression System
HEK293
Theoretical Molecular Weight
The protein has a predicted MW of 18.3 kDa. Due to glycosylation, the protein migrates to 40-50 kDa based on Bis-Tris PAGE result.
Purity
> 95% as determined by Bis-Tris PAGE
Endotoxin
Less than 1 EU per μg by the LAL method.
Buffer / Formulation
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
State
Lyophilized
Storage Conditions
-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Reconstitution Advice
Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.

Data Display

Bis-Tris PAGE
NKG2A-HB002 Bis-Tris-PAGE result

Biotinylated Human NKG2A on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

ELISA
NKG2A-HB002 ELISA result

Immobilized Biotinylated Human NKG2A, His Tag at 1μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Anti-NKG2A Antibody, hFc Tag with the EC50 of 5.3ng/ml determined by ELISA.

Background

NKG2, also known as NKG2A(CD159A), is a member of the killer cell lectin-like receptor family. NKG2A marks a unique immune effector subset preferentially co-expressing the tissue-resident CD103 molecule, but not immune checkpoint inhibitors. It is expressed only in NK-cells, but not in T-cells or B-cells.

References

  1. Vivier E. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells [J]. Cell. Volume 175, Issue 7, 13 December 2018, Pages 1731-1743.e13

Have questions about this product?

Our technical team can help with product selection, application questions and order support.

Contact Technical Support